 |
Corporate News
06-May-24
|
|
|
|
|
|
|
|
|
|
|
|
Lupin receives USFDA approval for Travoprost Ophthalmic Solution USP
|
|
|
|
|
|
|
|
Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), to market a generic equivalent to the reference listed drug (RLD) Travatan Z® Ophthalmic Solution, 0.004%, of Sandoz Inc. The product will be manufactured at Lupin's Pithampur facility in
India.
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Travoprost Ophthalmic Solution USP, 0.004% (RLD Travatan Z®), had estimated annual sales of USD 77 million in the U.S. (IQVIA MAT March 2024).
|
|
|
|
Previous News |
Lupin achieves ISO 14001 and ISO 45001 certification
(
Corporate News
-
15-May-24
18:12
)
|
|
|
Stock Alert: Indegene, Wipro, Biocon, HUDCO
(
Market Commentary
-
Stock Alert
13-May-24
08:28
)
|
|
|
Lupin grants 5,000 stock options under ESOP
(
Corporate News
-
10-May-24
17:55
)
|
|
|
Lupin commences shipment of Mirabegron ER Tablets to US
(
Corporate News
-
10-May-24
17:51
)
|
|
|
Lupin appoints Jeffrey Kindler and Alfonso Zulueta as Independent Directors on its Board
(
Corporate News
-
09-May-24
11:22
)
|
|
|
Lupin
(
Results
-
Analysis
07-May-24
11:15
)
|
|
|
Nifty ends near 22,300; realty shares tumbles
(
Market Commentary
-
Quick Review
07-May-24
15:53
)
|
|
|
Lupin slides as Q4 PAT drops 41% QoQ to Rs 359 cr
(
Hot Pursuit
-
07-May-24
12:02
)
|
|
|
Board of Lupin recommends final dividend
(
Corporate News
-
07-May-24
10:10
)
|
|
|
Benchmarks edge higher; breadth positive
(
Market Commentary
-
Mid-Session
07-May-24
09:41
)
|
|
|
Lupin, Godrej Consumer, Wipro to be watched
(
Market Commentary
-
Stock Alert
07-May-24
08:28
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|